Leal

Leal Health Study Reveals Prostate Cancer Patients More Actively Engaged in Seeking Clinical Trials Significantly Earlier in Their Journey Compared to Other Solid Tumor Patients

Retrieved on: 
Wednesday, January 31, 2024

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that it presented a poster at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which showed that prostate cancer patients' clinical trial search patterns differ dramatically from those with other solid tumors. Nearly half of prostate cancer patients sought clinical trial options as newly-diagnosed patients compared to about one-third of the patient population for other solid tumors.

Key Points: 
  • Nearly half of prostate cancer patients sought clinical trial options as newly-diagnosed patients compared to about one-third of the patient population for other solid tumors.
  • The poster, titled, "Prostate cancer patients consider clinical trial options significantly earlier in their journey compared to other solid tumor patients," analyzed 35,670 patient profiles on Leal's digital platform, comparing disease characteristics between those with prostate cancer and other cancer types, such as bladder, colon, lung and breast cancer.
  • Leal's study also explored the impact of digital clinical trial search patterns among prostate cancer patients.
  • Concluded Dr. Gaziel, "Despite the major interest coming from patients, there are fewer prostate cancer trial options available to newly diagnosed patients.

Leal Health Partners with the American Cancer Society to Host "Hope in the New Year" Webinar

Retrieved on: 
Monday, January 29, 2024

Emphasizing the pivotal role of patient empowerment, Tim highlighted the invaluable support offered by patient-centric organizations like Leal Health and the American Cancer Society.

Key Points: 
  • Emphasizing the pivotal role of patient empowerment, Tim highlighted the invaluable support offered by patient-centric organizations like Leal Health and the American Cancer Society.
  • The conversation also spotlighted the American Cancer Society's Hope Lodge program, an initiative that provides free lodging and support to cancer patients and their caregivers during treatment.
  • Together - with the American Cancer Society - we look forward to continuing to make strides against cancer and helping more patients in need."
  • "Our American Cancer Society Hope Lodges create a sense of community for cancer patients and their caregivers," said Chloe Lipman, Vice President of Community Development for the American Cancer Society.

Leal Health Presents Poster Highlighting Strong Correlation Between Education, Engagement and Access to Clinical Trials with Improved Outcomes of Breast Cancer Patients

Retrieved on: 
Monday, December 11, 2023

NEW YORK, Dec. 11, 2023 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that the Company presented a poster at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5th-9th, highlighting the critical relationship between education, engagement and access to cancer clinical trials, and improved outcomes of breast cancer patients.

Key Points: 
  • The presentation showcased data from a diverse cohort of 14,509 breast cancer patients, emphasizing the critical relationship between care access factors and overall survival.
  • Notably, the study utilized real-world CDC data to correlate survival, with multiple factors relevant for the identification and enrollment in oncology clinical trials.
  • Tzvia Bader, CEO of Leal Health, added, "It's evident that education and access are crucial for better patient care.
  • Looking ahead, our goal remains clear: to bridge knowledge gaps, remove access hurdles and democratize cancer care for all patients."

Monster Energy's Giovanni Vianna and Rayssa Leal Claim World Championship Titles in Street Skateboarding at SLS Super Crown World Championships in Brazil

Retrieved on: 
Wednesday, December 6, 2023

SÃO PAULO, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Let's welcome our new Street League Skateboarding (SLS) World Champions! Monster Energy congratulates team riders Giovanni Vianna and Rayssa Leal on taking first-place spots at the SLS Super Crown World Championships in São Paulo, Brazil.

Key Points: 
  • Monster Energy congratulates team riders Giovanni Vianna and Rayssa Leal on taking first-place spots at the SLS Super Crown World Championships in São Paulo, Brazil.
  • Monster Energy congratulates team riders Giovanni Vianna and Rayssa Leal on taking first-place spots at the SLS Super Crown World Championships in São Paulo, Brazil.
  • - Rayssa Leal
    In the official world championship event presented by Street League Skateboarding (SLS), 22-year-old Vianna from Santo Andre, Brazil, earned the title in the down-to-the-wire Men's Street Skateboarding final.
  • In the Women's Street Skateboarding final, 15-year-old Leal from Imperatriz, Brazil, took first place to claim her second career SLS Super Crown World Championship title in front of an ecstatic hometown crowd.

Leal Health Leverages Generative AI to Optimize Cancer Treatment Matching for Patients

Retrieved on: 
Wednesday, December 6, 2023

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today the addition of generative AI ("GenAI") capabilities to its proprietary treatment platform for cancer patients. With this breakthrough, patented technology, Leal removes barriers between precision medicine and cancer patients searching for a cure, giving patients increased access to the most effective treatment options available (both clinical trials and standard-of-care therapies) for their exact diagnosis, regardless of their existing medical knowledge or understanding.

Key Points: 
  • NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today the addition of generative AI ("GenAI") capabilities to its proprietary treatment platform for cancer patients.
  • This leads to accurate treatment matches tailored to patients' specific medical data, as well as helps patients make the right decisions for their unique treatment journeys, based on the information they learn and receive.
  • "Leal is leveraging the power of GenAI to revolutionize cancer patients' access to precise treatment across the globe.
  • With this important addition to the platform, Leal is optimizing the treatment matching process for patients, ensuring that patient preferences are incorporated, and biases are overcome," added Bader.

Monster Energy's Rayssa Leal Takes Second Place at SLS Sydney 2023 Street Skateboarding Contest

Retrieved on: 
Wednesday, October 11, 2023

SYDNEY, Oct. 11, 2023 /PRNewswire/ -- Back on the podium! Monster Energy congratulates team rider Rayssa Leal on taking second place in Women's Skateboard Street at SLS Sydney 2023. In the official third contest of the 2023 SLS Championship Tour presented by Street League Skateboarding (SLS), the 15-year-old Leal from Imperatriz, Brazil, returned to the podium in a down-to-the-wire final.

Key Points: 
  • Monster Energy congratulates team rider Rayssa Leal on taking second place in Women's Skateboard Street at SLS Sydney 2023.
  • Monster Energy congratulates team rider Rayssa Leal on taking second place in Women's Skateboard Street at SLS Sydney 2023.
  • In the official third contest of the 2023 SLS Championship Tour presented by Street League Skateboarding (SLS), the 15-year-old Leal from Imperatriz, Brazil, returned to the podium in a down-to-the-wire final.
  • Contested at Ken Rosewall Arena from October 6-7, SLS Sydney marked the third stop of the 2023 SLS World Championship Tour.

Leal Health Presents Poster Highlighting Disparities in Clinical Trial Participation Among Diverse Ethnic Groups

Retrieved on: 
Tuesday, October 10, 2023

NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Leal Health ("Leal'' or the "Company''), formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced today that it presented a poster highlighting disparities in clinical trial participation among diverse ethnic communities at this year's American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial / Ethnic Minorities and the Medically Underserved.

Key Points: 
  • The poster, titled, "Unveiling disparities in clinical trial participation: Exploring socioeconomic barriers and access to insurance among diverse ethnic groups," was presented by Ritta Jubran, Medical Director at Leal Health, and highlighted data from a multi-ethnic cohort of 4,525 new patient sign-ups in 2023.
  • Key findings from the study include:
    Non-white patients were more likely to be uninsured compared to white patients.
  • Fifty percent of non-white patients limited their search radius for clinical trials to 50 miles, compared to 42 percent of white patients.
  • With over 40 percent of the 150,000+ patients in the Leal community who come from diverse ethnic groups, we have the tools and data to help pharma identify the real barriers and help mitigate these issues that will, in turn, improve accessibility and participation of more diverse patient populations in clinical trials."

Leal Health Presents Poster Highlighting Impact of Patient ECOG Scores on Oncology Clinical Trial Eligibility

Retrieved on: 
Monday, August 7, 2023

NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Leal Health ("Leal" or "the Company"), formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced today that the Company presented a poster at this year's American Society of Clinical Oncology (ASCO) Breakthrough Annual Meeting, showcasing the impact of patients' ECOG scores on solid and non-solid tumor clinical trial eligibility. The poster was presented by Lena Lapidot, Ph.D., RD, Medical Director at Leal Health.

Key Points: 
  • Leal's study evaluated the impact of ECOG scores on solid and non-solid tumor clinical trial eligibility.
  • These profiles include unique factors relevant to clinical trial eligibility, including disease status, stage, biomarkers, treatment history, comorbidities and demographics.
  • To assess the impact of patients' ECOG scores, Leal adjusted the dataset to reflect a better ECOG score per patient while all other parameters remained constant.
  • In a dataset of 5,018 patients, those with higher ECOG scores (2 or 3) were matched to significantly fewer clinical trials, negatively impacting patients' trial options.

Leal Health Becomes Industry's First and Only Single Point of Access to FDA-Approved Treatments and Clinical Trials for Cancer Patients

Retrieved on: 
Tuesday, June 20, 2023

NEW YORK, June 20, 2023  /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced today that it has expanded its platform to include FDA-approved cancer treatment decision support, becoming the industry's first and only tool that offers patients seeking the best treatment options a single point of access to all relevant FDA-approved, standard-of-care treatments and clinical trials. Leal's proprietary AI technology platform matches patients with all available treatments based on their unique medical profiles, biomarkers, treatment preferences and more.

Key Points: 
  • Leal's proprietary AI technology platform matches patients with all available treatments based on their unique medical profiles, biomarkers, treatment preferences and more.
  • "With Leal, patients receive all of their treatment options quickly and clearly so that they can focus on working with their doctors to determine the most effective course of action."
  • Leal further informs patients by directing them to optional treatments for their consideration.
  • We have also become the first platform to offer a true end-to-end patient-centric solution that connects patients, oncologists and the pharmaceutical industry to provide unbiased access to cancer treatments for all."

Leal Health Launches New AI Feature to Simplify Interpretation of Genetic Testing and Provide Minorities Increased Access to Clinical Trial and Cancer Treatments

Retrieved on: 
Wednesday, June 7, 2023

NEW YORK, June 7, 2023 /PRNewswire/ -- Leal Health ("Leal" or "the Company"), formerly known as Trialjectory, an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced today that it has launched a new AI feature that can interpret and translate the results of genetic tests for cancer patients. This is an important development that is expected to remove barriers patients have in accessing advanced care and clinical trials.

Key Points: 
  • This is an important development that is expected to remove barriers patients have in accessing advanced care and clinical trials.
  • Data from a study conducted by Leal Health which was presented as an e-publication by the Company at this year's American Society of Clinical Oncology (ASCO) Annual Meeting , highlighted racial disparities in cancer treatment.
  • To address this issue, Leal launched a platform feature that allows patients to upload their genetic test results and have them analyzed against a proprietary AI algorithm.
  • By simplifying the interpretation of genetic test results, patients are able to intelligently and actively participate in the decision-making process with their oncologists."